RoadMap ↓
Showing 25 events
About Us
Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies
Company Overview
Pharmazz, Inc. is a commercial-stage biopharmaceutical innovator dedicated to developing first-in-class therapeutics for critical care medicine. Founded in 2010 by Professor (Dr.) Anil Gulati, the company has successfully bridged elite academic research with global commercial execution. Shortly after its inception, Mr. Ajit Srimal joined the executive leadership team to strengthen the company’s corporate strategy and operational scaling.Pharmazz operates a unique, capital-efficient, dual-engine model anchored by two breakthrough molecules—Sovateltide and Centhaquine—which address critical, unmet needs in acute ischemic stroke, resuscitative care, and neurodegenerative disorders.
Foundational History & Strategic Growth
Pharmazz’s early strategy relied heavily on bridging top-tier academic research with commercial drug development. In January 2011, the company executed an exclusive licensing agreement with Midwestern University, followed by a subsequent licensing agreement with the University of Illinois in January 2014.
To manage its growing global footprint, Pharmazz India Private Limited was established in March 2011, with Dr. Sunil Gulati overseeing Operations and Dr. Manish Lavhale heading the scientific division. These foundational years secured the intellectual property that would form the bedrock of the company’s pipeline: Centhaquine and Sovateltide.
Core Therapeutic Pipeline
-
Sovateltide (Tyvalzi™ / Tycamzzi®):
A novel Endothelin-B receptor agonist that drives neurovascular remodeling by stimulating neurogenesis, angiogenesis, and mitochondrial biogenesis rather than merely limiting acute cellular damage.
- Indications: Acute Ischemic Stroke, Alzheimer's Disease (AD), Traumatic Brain Injury (TBI).
- Commercial Status: Marketed in India for acute cerebral ischemic stroke as Tyvalzi™ by Sun Pharmaceuticals.
- Clinical Status: Pharmazz is actively conducting its global pivotal Phase III trial (RESPECT-ETB), which is expanding to 81 sites worldwide.
-
Centhaquine (Lyfaquin®):
A novel resuscitative agent that increases cardiac output and reverses shock without inducing dangerous arterial constriction. It is delivered via standard peripheral IV—no central venous line required.
- Indications: Hypovolemic Shock, Acute Respiratory Distress Syndrome (ARDS).
- Commercial Status: Commercially launched in India as Lyfaquin®.
- Clinical Status: Cleared for Phase III clinical progression by the US FDA for hypovolemic shock, and currently in Phase II testing for ARDS.